García-Rodríguez, J. (Javier)

Filtering

2011 - 20182

Settings

Author search.filters.isAuthorOfPublication.7cfd921f-e75c-45e5-86cc-40d4c368dd7b

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Aprovechando que el Esgueva…: Góngora (y Quevedo) en la corte vallisoletana (1603)
    (Servicio de Publicaciones de la Universidad de Navarra, 2011-07) García-Rodríguez, J. (Javier); Conde-Parrado, P. (Pedro)
    Estudio del «primer episodio» de la supuesta polémica literaria mantenida por Francisco de Quevedo y Luis de Góngora. El escenario se ubica en Valladolid, donde dos años antes (1601) se ha establecido la corte y adonde llega el poeta cordobés a cumplir un encargo del cabildo de su ciudad. Se analiza su producción poética inspirada por dicha estancia de unos pocos meses y las razones que en ella pudo hallar Quevedo para decidirse a lanzar su ataque contra él, así como la respuesta que habría recibido, en el que sería uno de los primeros testimonios de recepción de la obra quevedesca. Se ofrece la edición crítica anotada de cinco textos, además de su exégesis, procurando respetar en todo momento su realidad ecdótica y el estricto «estado de la cuestión» que de ellos se deduce, sin extraer conclusiones categóricas de difícil demostración: la polémica entre ambos genios no parece inexistente, como algunos han pretendido, pero los escasos datos con que se cuenta tampoco deben forzarse hasta dar una imagen excesivamente desvirtuada de la polémica. Sin abandonar el terreno de la hipótesis, salvo cuando esos datos lo permiten, se analiza «lo que hay» (los textos) y se apuntan verosímiles posibilidades de «lo que probablemente hubo» (un crudo enfrentamiento que luego se mantendría en el tiempo).------------------------------------------------------------------------------------ This article studies the «first episode» of the alleged literary skirmish between Góngora and Quevedo. The scene takes place in Valladolid, where the court had settled two years before (1601) and where the poet from Córdoba arrives to take charge of a commission for its cathedral’s Cabildo. The poetic production of that few-months-long stay is studied, as well, together with the reasons that Quevedo might have found to attack Góngora and the latter’s counterattack, in what might be considered as one of the earliest accounts of the reception of Quevedo’s works. The article also includes the critical, annotated edition of five texts, with their exegesis, while trying to respect, at all times, their ecdotical reality and the status quaestionis inferred from them, without drawing difficult-to-prove categorical conclusions. The quarrel between both geniuses does not seem inexistent, as some critics defended, but the scarcity of the data that we have at our disposal should not be forced to the extent of giving a distorted image of it. Without leaving hypothetical ground, except when facts allow us to, we analyze what we have got (the texts themselves) and advance probable possibilities of what probably happened (a raw confrontation sustained over time).
  • Thumbnail Image
    A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
    (National Library of Medicine, 2018) Chopitea, A. (Ana); Alfaro, C. (Carlos); Rotellar, F. (Fernando); García-Rodríguez, J. (Javier); Perez-Gracia, J.L. (Jose Luis); Viudez, A. (Antonio); Rodriguez, I. (Inmaculada); Rodriguez-Ruiz, M.E. (María Esperanza); Lopez-Diaz-de-Cerio, A. (Ascensión); Castañon, E. (Eduardo); Oñate, C. (Carmen); Inoges, S. (Susana); Ponz-Sarvise, M. (Mariano); Melero, I. (Ignacio); Perez, G. (Guiomar); Resano, L. (Leyre); Vera, R. (Ruth)
    Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8. 74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88).